7.87
0.08 (1.03%)
| Penutupan Terdahulu | 7.79 |
| Buka | 7.80 |
| Jumlah Dagangan | 1,304,684 |
| Purata Dagangan (3B) | 2,468,491 |
| Modal Pasaran | 574,442,304 |
| Harga / Jualan (P/S) | 1.32 |
| Harga / Buku (P/B) | 0.860 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Jul 2025 |
| Margin Keuntungan | -10.92% |
| Margin Operasi (TTM) | 37.82% |
| EPS Cair (TTM) | -0.660 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 646.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.59% |
| Nisbah Semasa (MRQ) | 4.58 |
| Aliran Tunai Operasi (OCF TTM) | -250.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.69 M |
| Pulangan Atas Aset (ROA TTM) | -5.39% |
| Pulangan Atas Ekuiti (ROE TTM) | -7.34% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Arvinas, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.50 |
|
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.74% |
| % Dimiliki oleh Institusi | 91.08% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| New Leaf Venture Partners, L.L.C. | 31 Mar 2025 | 1,585,721 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 24.00 (HC Wainwright & Co., 204.96%) | Beli |
| Median | 11.00 (39.77%) | |
| Rendah | 8.00 (Goldman Sachs, 1.65%) | Pegang |
| Purata | 13.73 (74.46%) | |
| Jumlah | 7 Beli, 6 Pegang | |
| Harga Purata @ Panggilan | 7.47 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Leerink Partners | 02 Jun 2025 | 9.00 (14.36%) | Pegang | 7.33 |
| UBS | 15 May 2025 | 21.00 (166.84%) | Beli | 6.26 |
| Morgan Stanley | 09 May 2025 | 11.00 (39.77%) | Pegang | 6.61 |
| BMO Capital | 05 May 2025 | 10.00 (27.06%) | Beli | 7.63 |
| Citigroup | 05 May 2025 | 9.50 (20.71%) | Pegang | 7.63 |
| Truist Securities | 05 May 2025 | 11.00 (39.77%) | Pegang | 7.63 |
| Barclays | 02 May 2025 | 16.00 (103.30%) | Beli | 7.72 |
| Goldman Sachs | 02 May 2025 | 8.00 (1.65%) | Pegang | 7.72 |
| 17 Apr 2025 | 12.00 (52.48%) | Pegang | 8.60 | |
| Guggenheim | 02 May 2025 | 16.00 (103.30%) | Beli | 7.72 |
| HC Wainwright & Co. | 02 May 2025 | 24.00 (204.96%) | Beli | 7.72 |
| Jefferies | 02 May 2025 | 10.00 (27.06%) | Pegang | 7.72 |
| Piper Sandler | 02 May 2025 | 14.00 (77.89%) | Beli | 7.72 |
| Wells Fargo | 02 May 2025 | 19.00 (141.42%) | Beli | 7.72 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |